PEOPLE OF COLOR & PSORIATIC DISEASE

A History of Inequity in Psoriatic Disease

Data on the clinical presentation of plaque psoriasis (PsO) in people of color is scarce and there have been few studies that specifically study its severity in different races and ethnicities.1,2 Similarly, there is limited research concerning ethnic differences for psoriatic arthritis (PsA), which may be influenced by a number of genetic, lifestyle and cultural factors.3,4

There is a long history of inequitable medical care in people of color living with psoriatic disease – including time to diagnosis, misdiagnosis and limited access to diagnostic testing.2,5,6 There is a critical unmet need that must be addressed with new solutions that help close these gaps.

More than

50%
of people with PsA experience
at least a 2-year delay from
symptoms to diagnosis.5

People of color with PsO and PsA have reported a

LOWER
quality of life as a result of the disease,
compared with white patients.2,4

72%
of non-white patients
say PsO interferes with their
capacity to enjoy life.7

> VIEW REFERENCES

Hear From Our Members

Together we’re supporting the creation of tangible solutions for obstacles that exist and persist for people of color navigating psoriatic disease.

Grace Wright, MD, PhD

Rheumatologist

Davia Roberts, LPC

Licensed Therapist

Howard Chang

Plaque Psoriasis Patient Advocate

A Guide for More Equitable Care

If you’re a healthcare professional, Beyond the Textbook includes information that can lead to improved care and patient outcomes. If you’re living with or are a caregiver to someone with psoriatic disease, consider sharing this resource with your doctor at your next appointment.
READ MORE ABOUT BEYOND THE TEXTBOOK
© Janssen Pharmaceuticals, Inc. 2024. All Rights Reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc. This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.
Last Updated: March 20, 2024
cp-439536v1
X-twitter Linkedin Youtube

Cookie Policy

Privacy Policy | Do Not Sell or Share My Personal Information | Legal Notice | Limit the Use of My Sensitive Personal Information

1Kerr GS, Qaiyumi S, Richards J, et al. Psoriasis and psoriatic arthritis in African-American patients–the need to measure disease burden. Clin Rheumatol. 2015;34(10):1753-1759.

2Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16-24.

3About Psoriatic Arthritis. National Psoriasis Foundation. Updated November 24, 2021. Accessed May 1, 2024. https://www.psoriasis.org/about-psoriatic-arthritis/

4Aslam T, Mahmood F, Sabanathan A, Waxman R, Helliwell PS. A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. Rheumatology. 2021 Jan; 60(1):340-345.

5Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. J Rheumatol. 2021;48(9):1-15.

6Psoriasis Statistics. National Psoriasis Foundation. Updated October 8, 2021. Accessed May 1, 2024. https://www.psoriasis.org/psoriasis-statistics/

7(2009). Report on the Psycho-Social Impacts of Psoriasis. The National Psoriasis Foundation.